{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Sensei Biotherapeutics, Inc."},"Symbol":{"label":"Symbol","value":"SNSE"},"Address":{"label":"Address","value":"451 D STREET,SUITE 710, BOSTON, Massachusetts, 02210, United States"},"Phone":{"label":"Phone","value":"+1 240 243-8000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The company's ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused, and coordinated innate and adaptive immune response."},"CompanyUrl":{"label":"Company Url","value":"https://www.senseibio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alice Drumheller","title":"Vice President-Clinical Operations"},{"name":"Edward van der Horst","title":"Chief Scientific Officer"},{"name":"John K. Celebi","title":"President, Chief Executive Officer & Director"},{"name":"Ron Weitzman","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}